Text Size

Nelfinavir and M8 Drug-Level Monitoring in HIV-1 Infection

The recruitment status of this study is unknown because the information has not been verified recently.
Verified September 2005 by University of Wisconsin, Madison.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Agouron Pharmaceuticals
Information provided by:
University of Wisconsin, Madison
ClinicalTrials.gov Identifier:
NCT00205283
First received: September 13, 2005
Last updated: October 29, 2007
Last verified: September 2005
History of Changes
  Purpose

The purpose of this study is to assess the impact of prospective drug level monitoring and dose-adjustment of nelfinavir (NFV) on the clinical and virologic outcomes in a group of HIV-infected patients who have achieved virologic success while receiving a nelfinavir containing highly active antiretroviral therapy (HAART) regimen.


Condition Intervention
HIV Infections
 Drug: Nelfinavir

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Nelfinavir and M8 Drug-Level Monitoring in HIV-1 Infection

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS
U.S. FDA Resources

Further study details as provided by University of Wisconsin, Madison:

Primary Outcome Measures:
  • Virologic response
  • Nelfinavir pharmacokinetics

Secondary Outcome Measures:
  • Impact of nelfinavir and M8 pharmacokinetics on virologic response

Estimated Enrollment: 20
Study Start Date: August 2003
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Antiretroviral naive or currently taking a nelfinavir containing HAART regimen where nelfinavir is the first protease inhibitor
  • Patients willing to comply with the protocol
  • Age greater than or equal to 18 years
  • Virologically successful if already on an established regimen

Exclusion Criteria:

  • Prior use of a protease inhibitor exclusive of nelfinavir
  • Required use or concomitant use of drugs that may interact with or are contraindicated with nelfinavir
  • Use of immunomodulators or vaccines for HIV disease
  • Intercurrent illness at the time of enrollment that, in the clinician's judgement, could influence the HIV RNA concentration
  • Baseline ALT levels greater than five times the upper limit of normal
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00205283

Contacts
Contact: Andrew Urban, MD 608-256-1901 ext 17472 andrew.urban@med.va.gov
Contact: Frank Graziano, MD, PhD 608-263-6186 fmg@medicine.wisc.edu

Locations
United States, Wisconsin
University of Wisconsin Hospital and Clinics Recruiting
Madison, Wisconsin, United States, 53792
Contact: Andrew Urban, MD     608-256-1901 ext 17472     andrew.urban@med.va.gov    
Sponsors and Collaborators
University of Wisconsin, Madison
Agouron Pharmaceuticals
Investigators
Principal Investigator: Andrew Urban, MD University of Wisconsin Hospital and Clinics
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00205283     History of Changes
Other Study ID Numbers: 2002-212
Study First Received: September 13, 2005
Last Updated: October 29, 2007
Health Authority: United States: Institutional Review Board

Keywords provided by University of Wisconsin, Madison:
HIV

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases
 Nelfinavir
HIV Protease Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Anti-HIV Agents
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on June 13, 2013